85 related articles for article (PubMed ID: 31516031)
1. 'Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib.
Aljoundi AK; Agoni C; Olotu FA; Soliman ME
Future Med Chem; 2019 Sep; 11(18):2365-2380. PubMed ID: 31516031
[No Abstract] [Full Text] [Related]
2. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Williams NK; Lucet IS; Klinken SP; Ingley E; Rossjohn J
J Biol Chem; 2009 Jan; 284(1):284-291. PubMed ID: 18984583
[TBL] [Abstract][Full Text] [Related]
4. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Battistello E; Katanayeva N; Dheilly E; Tavernari D; Donaldson MC; Bonsignore L; Thome M; Christie AL; Murakami MA; Michielin O; Ciriello G; Zoete V; Oricchio E
Blood; 2018 May; 131(21):2345-2356. PubMed ID: 29567799
[TBL] [Abstract][Full Text] [Related]
5. Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).
Fu T; Zuo Y; Zhong Z; Chen X; Pan Z
Eur J Med Chem; 2022 Feb; 229():114051. PubMed ID: 34952433
[TBL] [Abstract][Full Text] [Related]
6. Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights.
Kohal R; Bhavana ; Kumari P; Sharma AK; Gupta GD; Verma SK
Bioorg Med Chem Lett; 2024 Apr; 102():129674. PubMed ID: 38408513
[TBL] [Abstract][Full Text] [Related]
7. Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors.
Francini CM; Fallacara AL; Artusi R; Mennuni L; Calgani A; Angelucci A; Schenone S; Botta M
ChemMedChem; 2015 Dec; 10(12):2027-41. PubMed ID: 26514807
[TBL] [Abstract][Full Text] [Related]
8. GRID and docking analyses reveal a molecular basis for flavonoid inhibition of Src family kinase activity.
Wright B; Watson KA; McGuffin LJ; Lovegrove JA; Gibbins JM
J Nutr Biochem; 2015 Nov; 26(11):1156-65. PubMed ID: 26140983
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of Fyn and Lyn in their N-terminal unique regions during induction of apoptosis: a new mechanism for Src kinase regulation.
Luciano F; Ricci JE; Auberger P
Oncogene; 2001 Aug; 20(36):4935-41. PubMed ID: 11526478
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
11. Towards simple kinetic models of functional dynamics for a kinase subfamily.
Sultan MM; Kiss G; Pande VS
Nat Chem; 2018 Sep; 10(9):903-909. PubMed ID: 29988151
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
[TBL] [Abstract][Full Text] [Related]
14. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
16. The three-dimensional solution structure of the SH2 domain from p55blk kinase.
Metzler WJ; Leiting B; Pryor K; Mueller L; Farmer BT
Biochemistry; 1996 May; 35(20):6201-11. PubMed ID: 8639560
[TBL] [Abstract][Full Text] [Related]
17. Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c-Src and Syk as assessed by phage display.
Schmitz R; Baumann G; Gram H
J Mol Biol; 1996 Aug; 260(5):664-77. PubMed ID: 8709147
[TBL] [Abstract][Full Text] [Related]
18. Identification and activation of Src family kinases in primary megakaryocytes.
Lannutti BJ; Shim MH; Blake N; Reems JA; Drachman JG
Exp Hematol; 2003 Dec; 31(12):1268-74. PubMed ID: 14662334
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the inhibitor recognition of human Lyn kinase domain.
Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
[TBL] [Abstract][Full Text] [Related]
20. In Silico Reoptimization of Binding Affinity and Drug-Resistance Circumvention Ability in Kinase Inhibitors: A Case Study with RL-45 and Src Kinase.
Koneru JK; Sinha S; Mondal J
J Phys Chem B; 2019 Aug; 123(31):6664-6672. PubMed ID: 31310546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
